Clinical Effect on the Treatment of Alzheimer Disease with Sodium Oligomannate Combined with Intermittent θ Burst Stimulation

GUO Junnan; ZHOU Shufang; YANG Xiaojing; CHANG Na

doi:10.3969/j.issn.1004-437X.2026.12.020

Abstract：Objective To analyze the clinical therapeutic effect of sodium oligomannate combined with intermittent θ burst stimulation(iTBS)on Alzheimer disease(AD)patients.Methods A prospective randomized controlled study was conducted to divide 104 AD patients admitted to Huaihe Hospital of Henan University from January 2021 to May 2024 into a control group and an observation group using a random number table method,with 52 patients in each group.The control group was treated with sodium oligomannate,and on this basis,the observation group was treated with iTBS,all were treated for 3 months.The cognitive function[Montreal cognitive assessment(MoCA),Alzheimer disease assessment scale-cognitive(ADAS-cog)],neurological function[5-hydroxytryptamine(5-HT),γ-aminobutyric acid(GABA),AD-associated neuronal thread protein(AD7 c-NTP)]and daily living ability[AD cooperative study-activities of daily living(ADCS-ADL)]were compared between the two groups before and after treatment.Results After 3 months of treatment,the MoCA and ADCS-ADL scores,5-HT and GABA levels increased in both groups,while the ADAS-cog score and AD7 c-NTP levels decreased.The MoCA and ADCS-ADL scores,5-HT and GABA levels in the observation group were higher than those in the control group,while the ADAS-cog score and AD7c-NTP levels were lower than those in the control group,with statistical significance(P＜0.05).Conclusion The combination of sodium oligomannate and iTBS therapy can significantly improve cognitive function,promote neurological recovery,and enhance daily living abilities in AD patients,with certain clinical application value.